Dr. Sharifi Appointed AAAS Fellow

Nima Sharifi, MD, Department of Cancer Biology, was named a Fellow of the American Association for the Advancement of Science (AAAS) by his peers. He joins 12 of his distinguished Cleveland Clinic colleagues named to this elite group of scientists.

AAAS is the world's largest multidisciplinary scientific society committed to advancing science, engineering and innovation and a leading publisher of cutting-edge research. Dr. Sharifi and nearly 400 other AAAS members-named-fellows will be honored at the AAAS Fellows Forum during the 2018 AAAS Annual Meeting in Austin, Texas on February 17. He is one of 40 new fellows appointed within the Section on Medical Sciences.

This honorable distinction recognizes Dr. Sharifi for his impactful contributions to the field of cancer biology, specifically his discoveries about steroid metabolism and disease-driving mechanisms of prostate cancer resistance to androgen deprivation therapies. His seminal discoveries identified and characterized a specific genetic variant that leads to more aggressive prostate cancer. His more recent studies demonstrated that this variant does in fact alter response to treatment in men and could potentially be used as a predictive biomarker when designing treatment regimens. His findings have also led to a first-in-human clinical trial taking place at Cleveland Clinic. The trial is led by Dr. Sharifi's colleague and co-director of the Center of Excellence for Prostate Cancer Research, Eric Klein, MD, chair of the Glickman Urological and Kidney Institute.

"I am very thankful for this recognition of my work," Dr. Sharifi said. "To be nominated by my peers makes it an even greater honor."

Dr. Sharifi is also a member of the Glickman Urological and Kidney Institute and Taussig Cancer Institute. He holds the Kendrick Family Chair for Prostate Cancer Research and co-directs the Center of Excellence for Prostate Cancer Research.

Read here for more information.